# Patent Claims

1. Use of L-dopa, its derivatives and physiologically compatible salts thereof for the prophylaxis of psychoses, particularly also of schizophrenia psychoses, as well as for the treatment of diseases which are caused by disrupted tyrosine transport or disrupted tyrosine decarboxylase.

2. Use of L-dopa, its derivatives and physiologically compatible salts thereof for the production of pharmaceuticals for the prophylaxis of psychoses, particularly also of schizophrenia psychoses, as well as for the treatment of diseases which are caused by disrupted tyrosine transport or disrupted tyrosine decarboxylase.

3. Use of L-dopa, its derivatives and physiologically compatible salts thereof according to claim 1 or 2 in combination with at least one enzyme inhibitor.

4. Use of L-dopa, its derivatives and physiologically compatible salts thereof according to claim 3, further characterized in that the enzyme inhibitor(s) involve decarboxylase inhibitors and/or catechol-O-methyltransferase inhibitors and/or monoamine oxidase inhibitors and/or β-hydroxylase inhibitors.

5. Use of L-dopa, its derivatives and physiologically compatible salts thereof according to claim 4, further characterized in that the decarboxylase inhibitor is selected from the group

consisting of D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), (-)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid (carbidopa), L- serine 2-(2,3,4-trihydroxybenzyl) hydrazide, glycine 2-(2,3,4-trihydroxybenzyl) hydrazide and L-tyrosine 2-(2,3,4-trihydroxybenzyl) hydrazide as well as their physiologically compatible salts.

6. Use of L-dopa, its derivatives and physiologically compatible salts thereof according to claim 4, further characterized in that the catechol-O-methyltransferase inhibitor is selected from entacapone and cabergoline as well as physiologically compatible salts thereof.

7. Use of L-dopa, its derivatives and physiologically compatible salts thereof according to claim 4, further characterized in that the monoamine oxidase inhibitor is selected from the group consisting of selegiline, moclobemide and tranylcypromine as well as physiologically compatible salts thereof.

8. Use of L-dopa, its derivatives and physiologically compatible salts thereof according to claim 4, further characterized in that the β-hydroxylase inhibitor is selected from calcium 5-butyl picolinate and calcium 5-pentyl picolinate as well as physiologically compatible salts thereof.